Warfarin vs. Asprin in Reduced Ejection Fraction
Warfarin vs. Asprin in Reduced Ejection Fraction
Warfarin vs. Asprin in Reduced Ejection Fraction
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
No. at Risk<br />
Primary Outcome<br />
Aspir<strong>in</strong> 4,033 patient years (320 endpo<strong>in</strong>ts; 7.93% per year)<br />
<strong>Warfar<strong>in</strong></strong> 4,045 patient years (302 endpo<strong>in</strong>ts; 7.47% per year)<br />
Overall HR = 0.93 (0.79-1.10) p=0.40<br />
Proportional Hazards<br />
assumption violated<br />
Primary Analysis: Tx by Time Interaction<br />
Aspir<strong>in</strong> 1163 1073 860 658 508 329 94<br />
<strong>Warfar<strong>in</strong></strong> 1142 1049 852 653 525 363 115<br />
aspir<strong>in</strong><br />
warfar<strong>in</strong>
Change language